Literature DB >> 33129806

Modulating phosphate consumption, a novel therapeutic approach for the control of cancer cell proliferation and tumorigenesis.

Jamie L Arnst1, George R Beck2.   

Abstract

Phosphorus, often in the form of inorganic phosphate (Pi), is critical to cellular function on many levels; it is required as an integral component of kinase signaling, in the formation and function of DNA and lipids, and energy metabolism in the form of ATP. Accordingly, crucial aspects of cell mitosis - such as DNA synthesis and ATP energy generation - elevate the cellular requirement for Pi, with rapidly dividing cells consuming increased levels. Mechanisms to sense, respond, acquire, accumulate, and potentially seek Pi have evolved to support highly proliferative cellular states such as injury and malignant transformation. As such, manipulating Pi availability to target rapidly dividing cells presents a novel strategy to reduce or prevent unrestrained cell growth. Currently, limited knowledge exists regarding how modulating Pi consumption by pre-cancerous cells might influence the initiation of aberrant growth during malignant transformation, and if reducing the bioavailability or suppressing Pi consumption by malignant cells could alter tumorigenesis. The concept of targeting Pi-regulated pathways and/or consumption by pre-cancerous or tumor cells represents a novel approach to cancer prevention and control, although current data remains insufficient as to rigorously assess the therapeutic value and physiological relevance of this strategy. With this review, we present a critical evaluation of the paradox of how an element critical to essential cellular functions can, when available in excess, influence and promote a cancer phenotype. Further, we conjecture how Pi manipulation could be utilized as a therapeutic intervention, either systemically or at the cell level, to ultimately suppress or treat cancer initiation and/or progression. Published by Elsevier Inc.

Entities:  

Keywords:  Cell proliferation; Dietary phosphate; Osteopontin; Phosphate addiction; Phosphate transport; Tumor progression

Year:  2020        PMID: 33129806     DOI: 10.1016/j.bcp.2020.114305

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  3 in total

1.  High SLC20A1 Expression Is Associated With Poor Prognosis for Radiotherapy of Estrogen Receptor-positive Breast Cancer.

Authors:  Chotaro Onaga; Shoma Tamori; Izumi Matsuoka; Ayaka Ozaki; Hitomi Motomura; Yuka Nagashima; Tsugumichi Sato; Keiko Sato; Kouji Tahata; Yuyun Xiong; Yoshio Nakano; Yasunari Mano; Satoru Miyazaki; Kazunori Sasaki; Shigeo Ohno; Kazunori Akimoto
Journal:  Cancer Diagn Progn       Date:  2022-07-03

2.  High expression of SLC20A1 is less effective for endocrine therapy and predicts late recurrence in ER-positive breast cancer.

Authors:  Chotaro Onaga; Shoma Tamori; Izumi Matsuoka; Ayaka Ozaki; Hitomi Motomura; Yuka Nagashima; Tsugumichi Sato; Keiko Sato; Yuyun Xiong; Kazunori Sasaki; Shigeo Ohno; Kazunori Akimoto
Journal:  PLoS One       Date:  2022-05-23       Impact factor: 3.752

3.  Effect of extracts from eggs of Helix aspersa maxima and Helix aspersa aspersa snails on Caco-2 colon cancer cells.

Authors:  Magdalena Matusiewicz; Karolina Marczak; Barbara Kwiecińska; Julia Kupis; Klara Zglińska; Tomasz Niemiec; Iwona Kosieradzka
Journal:  PeerJ       Date:  2022-04-12       Impact factor: 3.061

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.